Literature DB >> 26650233

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells.

Gregory J Baker1, Maria G Castro1, Pedro R Lowenstein2.   

Abstract

Our laboratory has recently demonstrated that natural killer (NK) cells are capable of eradicating orthotopically implanted mouse GL26 and rat CNS-1 malignant gliomas soon after intracranial engraftment if the cancer cells are rendered deficient in their expression of the β-galactoside-binding lectin galectin-1 (gal-1). More recent work now shows that a population of Gr-1+/CD11b+ myeloid cells is critical to this effect. To better understand the mechanisms by which NK and myeloid cells cooperate to confer gal-1-deficient tumor rejection we have developed a comprehensive protocol for the isolation and analysis of glioma-infiltrating peripheral blood mononuclear cells (PBMC). The method is demonstrated here by comparing PBMC infiltration into the tumor microenvironment of gal-1-expressing GL26 gliomas with those rendered gal-1-deficient via shRNA knockdown. The protocol begins with a description of how to culture and prepare GL26 cells for inoculation into the syngeneic C57BL/6J mouse brain. It then explains the steps involved in the isolation and flow cytometric analysis of glioma-infiltrating PBMCs from the early brain tumor microenvironment. The method is adaptable to a number of in vivo experimental designs in which temporal data on immune infiltration into the brain is required. The method is sensitive and highly reproducible, as glioma-infiltrating PBMCs can be isolated from intracranial tumors as soon as 24 hr post-tumor engraftment with similar cell counts observed from time point matched tumors throughout independent experiments. A single experimentalist can perform the method from brain harvesting to flow cytometric analysis of glioma-infiltrating PBMCs in roughly 4-6 hr depending on the number of samples to be analyzed. Alternative glioma models and/or cell-specific detection antibodies may also be used at the experimentalists' discretion to assess the infiltration of several other immune cell types of interest without the need for alterations to the overall procedure.

Entities:  

Year:  2015        PMID: 26650233      PMCID: PMC4692754          DOI: 10.3791/53676

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  31 in total

1.  Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.

Authors:  Yohei Mineharu; Gwendalyn D King; A K M G Muhammad; Serguei Bannykh; Kurt M Kroeger; Chunyan Liu; Pedro R Lowenstein; Maria G Castro
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses.

Authors:  Marcela Assanah; Richard Lochhead; Alfred Ogden; Jeffrey Bruce; James Goldman; Peter Canoll
Journal:  J Neurosci       Date:  2006-06-21       Impact factor: 6.167

3.  Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H.

Authors:  John Lynes; Mia Wibowo; Carl Koschmann; Gregory J Baker; Vandana Saxena; A K M G Muhammad; Niyati Bondale; Julia Klein; Hikmat Assi; Andrew P Lieberman; Maria G Castro; Pedro R Lowenstein
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

4.  Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology.

Authors:  Isaac Yang; Seunggu J Han; Michael E Sughrue; Tarik Tihan; Andrew T Parsa
Journal:  J Neurosurg       Date:  2011-06-10       Impact factor: 5.115

5.  Microglial/macrophage expression of interleukin 10 in human glioblastomas.

Authors:  S Wagner; S Czub; M Greif; G H Vince; N Süss; S Kerkau; P Rieckmann; W Roggendorf; K Roosen; J C Tonn
Journal:  Int J Cancer       Date:  1999-07-02       Impact factor: 7.396

6.  Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level.

Authors:  Justyna Kmiecik; Aurélie Poli; Nicolaas H C Brons; Andreas Waha; Geir Egil Eide; Per Øyvind Enger; Jacques Zimmer; Martha Chekenya
Journal:  J Neuroimmunol       Date:  2013-08-31       Impact factor: 3.478

7.  Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.

Authors:  Sumia Ali; Gwendalyn D King; James F Curtin; Marianela Candolfi; Weidong Xiong; Chunyan Liu; Mariana Puntel; Queng Cheng; Jesus Prieto; Antoni Ribas; Jerzy Kupiec-Weglinski; Nico van Rooijen; Hans Lassmann; Pedro R Lowenstein; Maria G Castro
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

8.  Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.

Authors:  Lene Uhrbom; Chengkai Dai; Joseph C Celestino; Marc K Rosenblum; Gregory N Fuller; Eric C Holland
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

9.  Tumor-associated macrophages in glioma: friend or foe?

Authors:  Benjamin C Kennedy; Christopher R Showers; David E Anderson; Lisa Anderson; Peter Canoll; Jeffrey N Bruce; Richard C E Anderson
Journal:  J Oncol       Date:  2013-05-08       Impact factor: 4.375

10.  The prevalence and phenotype of activated microglia/macrophages within the spinal cord of the hyperostotic mouse (twy/twy) changes in response to chronic progressive spinal cord compression: implications for human cervical compressive myelopathy.

Authors:  Takayuki Hirai; Kenzo Uchida; Hideaki Nakajima; Alexander Rodriguez Guerrero; Naoto Takeura; Shuji Watanabe; Daisuke Sugita; Ai Yoshida; William E B Johnson; Hisatoshi Baba
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

View more
  7 in total

1.  Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models.

Authors:  Mahmoud S Alghamri; Neha Kamran; Padma Kadiyala; Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Methods Enzymol       Date:  2019-06-18       Impact factor: 1.600

2.  Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells.

Authors:  Gregory J Baker; Peter Chockley; Daniel Zamler; Maria G Castro; Pedro R Lowenstein
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

3.  Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models.

Authors:  Mahmoud S Alghamri; Felipe J Núñez; Neha Kamran; Stephen Carney; David Altshuler; Pedro R Lowenstein; Maria G Castro
Journal:  Methods Enzymol       Date:  2019-06-08       Impact factor: 1.600

4.  Specimen Collection for Translational Studies in Hidradenitis Suppurativa.

Authors:  A S Byrd; Y Dina; U J Okoh; Q Q Quartey; C Carmona-Rivera; D W Williams; M L Kerns; R J Miller; L Petukhova; H B Naik; L A Barnes; W D Shipman; J A Caffrey; J M Sacks; S M Milner; O Aliu; K P Broderick; D Kim; H Liu; C A Dillen; R Ahn; J W Frew; M J Kaplan; S Kang; L A Garza; L S Miller; A Alavi; M A Lowes; G A Okoye
Journal:  Sci Rep       Date:  2019-08-21       Impact factor: 4.379

5.  G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy.

Authors:  Mahmoud S Alghamri; Brandon L McClellan; Ruthvik P Avvari; Rohit Thalla; Stephen Carney; Carson S Hartlage; Santiago Haase; Maria Ventosa; Ayman Taher; Neha Kamran; Li Zhang; Syed Mohd Faisal; Felipe J Núñez; María Belén Garcia-Fabiani; Wajd N Al-Holou; Daniel Orringer; Shawn Hervey-Jumper; Jason Heth; Parag G Patil; Karen Eddy; Sofia D Merajver; Peter J Ulintz; Joshua Welch; Chao Gao; Jialin Liu; Gabriel Núñez; Dolores Hambardzumyan; Pedro R Lowenstein; Maria G Castro
Journal:  Sci Adv       Date:  2021-09-29       Impact factor: 14.957

6.  Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.

Authors:  Xiudong Guan; Lanxin Luo; Gulnaz Begum; Gary Kohanbash; Qingkun Song; Aparna Rao; Nduka Amankulor; Baoshan Sun; Dandan Sun; Wang Jia
Journal:  J Exp Clin Cancer Res       Date:  2018-10-17

7.  A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1.

Authors:  Diana Shah; Andrea Comba; Syed M Faisal; Padma Kadiyala; Gregory J Baker; Mahmoud S Alghamri; Robert Doherty; Daniel Zamler; Gabriel Nuñez; Maria G Castro; Pedro R Lowenstein
Journal:  Oncoimmunology       Date:  2021-06-28       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.